Regulatory Q&A Forum

For a non-EU manufacturer of a connected medical device, such as a Software as a Medical Device (SaMD) that processes personal health data from users in the European Union, navigating compliance can b...

When a non-EU company plans its compliance budget for 2026, what key factors should be considered to accurately estimate the cost of appointing a GDPR Article 27 Representative? While it is not possi...

While the introduction of broad EU regulations, such as the EU Deforestation Regulation (EUDR), highlights the need for a formal in-region presence for non-EU businesses, medical device manufacturers ...

For non-EU medical device manufacturers, appointing an EU Authorized Representative (AR) is a mandatory step for placing products on the European market under regulations like the MDR. While a common ...

With recent modernizations to the FDA's quality management system regulations for medical devices, how does the role and responsibility of a designated U.S. Agent evolve? Foreign establishments are re...

Given that FDA regulations require foreign medical device establishments to designate a U.S. Agent, how should manufacturers strategically select or re-evaluate their agent in light of the mandatory t...

When planning for future regulatory compliance under the EU MDR, particularly for 2026 and beyond, how can manufacturers effectively evaluate and budget for a "Person Responsible for Regulatory Compli...

When planning budgets for 2026, how can medical device manufacturers accurately forecast the cost of engaging a "Person Responsible for Regulatory Compliance (PRRC) as a Service" under the EU MDR? Bey...

When a manufacturer develops a novel Class II in vitro diagnostic (IVD) device that incorporates software, what are the primary regulatory considerations to address for a premarket submission? Sponso...

With the European Chemicals Agency (ECHA) advancing its universal PFAS restriction proposal, non-EU manufacturers of substances, mixtures, and articles containing per- and polyfluoroalkyl substances f...

With the FDA's transition from the Quality System Regulation (QSR) to the new Quality Management System Regulation (QMSR) becoming effective on February 2, 2026, how should foreign medical device manu...

When a manufacturer develops a new, low-risk medical device, such as a simple software tool for organizing patient information or a basic patient-examination accessory, they may initially determine it...

While the FDA's risk-based classification system establishes that General Controls apply to all medical devices and Special Controls are required for most Class II devices, how does a sponsor translat...

For a medical device requiring patient contact, such as a new surgical instrument or catheter, how does a sponsor develop a robust and defensible biocompatibility evaluation plan for a 510(k) submissi...

The annual FDA medical device establishment registration and listing renewal, mandated between October 1st and December 31st, is a critical compliance activity. For establishments that manufacture or ...

When a medical device manufacturer receives an FDA Form 483 with observations pointing to systemic quality system deficiencies, such as inadequate CAPA procedures or gaps in design control documentati...

When a manufacturer develops a device with the same intended use as a predicate but incorporates novel technological characteristics—such as an AI-based diagnostic algorithm or a new composite materia...

While the FDA's performance goal for a 510(k) review is often cited as 90 FDA Days, experienced regulatory professionals understand that the total calendar time from submission to clearance is typical...

When a 510(k) submission for a Class II device, such as a novel patient monitor or orthopedic implant, receives a Refuse to Accept (RTA) hold, the 90-day review clock is paused, creating significant p...

When a medical device manufacturer receives an FDA Form 483 with observations citing systemic deficiencies, such as an inadequate CAPA process or insufficient process validation, what are the key stra...